Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.63 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415586 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29423393 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29493550 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL2558967 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL15480253 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29415589 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL16401903 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL2558970 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL22283176 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL23138547 | 0.94 | CASP3 (0.58) | CASP3MDM4TP53KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-4740967-A1 | LINKER-DRUG MOLECULE AND ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Escugen Biotechnology Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-4659809-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4257153-B1 | ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI FUDAN ZHANGJIANG BIO PHARMACEUTICAL CO LTD (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| EP-4631952-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| EP-3538539-B1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20140274907-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN SARL (CH) | 2014-09-18 | — | — | US | disclosed |
| EP-2751111-A1 | PYRROLOBENZODIAZEPINES | Spirogen Sàrl (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2014068443-A1 | SPLICEOSTATIN ANALOGS | PFIZER INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014068443-A1 | SPLICEOSTATIN ANALOGS | PFIZER INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2013053873-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN SÀRL (CH) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013053873-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN SÀRL (CH) | 2013-04-18 | — | — | WO | disclosed |
| US-5639859-A | Carboxylate protective groups, a process for their preparation, their coupling to a functional group, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-06-17 | — | — | US | disclosed |
| US-5439806-A | Carboxylate protective groups, a process for their preparation, their coupling to a functional group, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | CASP3 1235/4885MDM4 4129/4885TP53 117/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | CASP3 141/4885MDM4 669/4885TP53 57/4885 |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | SF3B5, SNRPA1, SF3B1 | CASP3 700/4885MDM4 3400/4885TP53 954/4885 |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | SLC3A2, MTCL3, SLC13A2 | CASP3 274/4885MDM4 2727/4885TP53 290/4885 |
| US-20140274907-A1 | PYRROLOBENZODIAZEPINES | HRH3, CNR1, HRH4 | CASP3 2513/4885MDM4 3548/4885TP53 4325/4885 |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | MGAT3, GALE, GPI | CASP3 4255/4885MDM4 4836/4885TP53 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.